Responsible Artificial Intelligence for Polypharmacy and Medication-Safety Risk in Older Adults: An Explainable FHIR-Based Clinical Decision-Support Framework

References

[1] AlQashqri, H. et al. (2023) ‘Renally inappropriate medications in the old population’, Journal of Clinical Medicine, 12.

[2] American Geriatrics Society Beers Criteria Update Expert Panel (2023) ‘American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults’, Journal of the American Geriatrics Society, 71(7), pp. 2052–2081.

[3] Correia, R.B., de Araújo, L.P., Mattos, M.M. and Rocha, L.M. (2019) ‘City-wide analysis of electronic health records reveals gender and age biases in the administration of known drug-drug interactions’, npj Digital Medicine, 2, 74.

[4] Davies, L.E., Spiers, G., Kingston, A., Todd, A. and Adamson, J. (2020) ‘Adverse outcomes of polypharmacy in older people: systematic review of reviews’, Journal of the American Medical Directors Association, 21(2), pp. 181–187.

[5] Dhalwani, N.N. et al. (2017) ‘Association between polypharmacy and falls in older adults: a longitudinal study from England’, BMJ Open, 7, e016358.

[6] Fick, D.M. et al. (2019) ‘American Geriatrics Society 2019 updated AGS Beers Criteria’, Journal of the American Geriatrics Society, 67(4), pp. 674–694.

[7] HL7 International (2019) FHIR Release 4. Ann Arbor, MI: Health Level Seven International.

[8] Liu, L.T., Dean, S., Rolf, E., Simchowitz, M. and Hardt, M. (2018) ‘Delayed impact of fair machine learning’, Proceedings of the 35th International Conference on Machine Learning, pp. 3150–3158.

[9] Machekera, G., Mtemeli, P.S., Dongo, M.M. et al. (2026) ‘An explainable deep learning framework for energy-efficient water and sewer reticulation infrastructure: Predicting project risk, pumping demand and sustainable construction performance’.

[10] Marasinghe, K.M. et al. (2015) ‘Computerised clinical decision support systems to improve medication safety in long-term care homes: a systematic review’, BMJ Open, 5, e006539.

[11] Mouazer, A. et al. (2024) ‘A randomized simulation trial evaluating ABiMed, a clinical decision support system for medication reviews and polypharmacy management’, preprint.

[12] Munar, M.Y. and Singh, H. (2007) ‘Drug dosing adjustments in patients with chronic kidney disease’, American Family Physician, 75(10), pp. 1487–1496.

[13] Mupa, M.N. et al. (2026a) ‘Operationalizing AI at scale: Repeatable frameworks for integration, adoption and performance measurement across enterprise and startup environments’, World Journal of Advanced Research and Reviews.

[14] Mupa, M.N. et al. (2026b) ‘Applied machine learning frameworks for workflow optimization, organizational efficiency and digital transformation’, World Journal of Advanced Research and Reviews.

[15] Ng, Y. et al. (2025) ‘Evaluating the role of clinical decision support systems in improving prescribing for older people: a systematic review’, BMC Geriatrics.

[16] Obermeyer, Z., Powers, B., Vogeli, C. and Mullainathan, S. (2019) ‘Dissecting racial bias in an algorithm used to manage the health of populations’, Science, 366(6464), pp. 447–453.

[17] Očovská, Z. et al. (2024) ‘Renal drug dosage adjustments and adverse drug events in older adults’, Expert Opinion on Drug Safety.

[18] Page, A.T. et al. (2023) ‘Polypharmacy and medicine regimens in older adults in residential aged care’, Archives of Gerontology and Geriatrics.

[19] Rajkomar, A., Hardt, M., Howell, M.D., Corrado, G. and Chin, M.H. (2018) ‘Ensuring fairness in machine learning to advance health equity’, Annals of Internal Medicine, 169(12), pp. 866–872.

[20] Shah, B.M. and Hajjar, E.R. (2012) ‘Polypharmacy, adverse drug reactions, and geriatric syndromes’, Clinics in Geriatric Medicine, 28(2), pp. 173–186.

[21] Wang, N. and Taylor, C.O. (2023) ‘Drug Interaction Vectors Neural Network: DrIVeNN’, arXiv:2308.13891.

[22] Wiens, J. et al. (2019) ‘Do no harm: a roadmap for responsible machine learning for health care’, Nature Medicine, 25, pp. 1337–1340.

[23] Xue, L. et al. (2021) ‘Persistent polypharmacy and fall injury risk: the Health, Aging and Body Composition Study’, BMC Geriatrics, 21, 710.

[24] Zazzara, M.B. et al. (2021) ‘Adverse drug reactions in older adults: a narrative review of the literature’, European Geriatric Medicine, 12, pp. 463–473.

@article{1720286,
      author = {Kwame Ofori Boakye, Grace Mupa, Rumbidzai Lyn Kasinamunda, Rudorwashe Tsitsi Karuma, Munashe Naphtali Mupa},
      title = {Responsible Artificial Intelligence for Polypharmacy and Medication-Safety Risk in Older Adults: An Explainable FHIR-Based Clinical Decision-Support Framework},
      journal = {Iconic Research And Engineering Journals},
      year = {2026},
      volume = {10},
      number = {1},
      pages = {4031-4044},
      issn = {2456-8880},
      url = {https://www.irejournals.com/formatedpaper/1720286.pdf},
      abstract = {Medication-related harm in older adults is driven by the interaction of multimorbidity, age-related pharmacokinetic change, polypharmacy, potentially inappropriate medications, drug-drug interactions, fall-risk-increasing drugs and impaired renal function. Existing electronic prescribing alerts often treat these risks as isolated rules, generating high alert burden without ranking residents according to the combined probability and clinical significance of harm. This study develops an explainable, FHIR-based and fairness-aware clinical decision-support framework for identifying potentially inappropriate medications, high-risk combinations, excessive medication burden, medication-related fall risk, renal- and age-sensitive prescribing risks, and residents requiring pharmacist or clinical review. Because no single openly accessible Kaggle dataset contains all medication, laboratory, renal, fall and long-term-care variables needed for the full framework, a reproducible synthetic cohort of 10,000 older residents across 30 facilities was calibrated to the Kaggle Drug Adverse Event Detection Dataset, public adverse-drug-event datasets and relationships reported in geriatric pharmacotherapy literature. Logistic regression, random forest and gradient boosting models were compared using facility-level holdout validation. Performance was assessed with AUROC, area under the precision-recall curve, Brier score, sensitivity, specificity, positive predictive value and F1 score. Fairness was evaluated by sex, race and chronic-kidney-disease status at a capacity-constrained top-quintile review threshold. Logistic regression produced the most transportable discrimination across medication harm, medication-related falls and pharmacist-review need, while calibration and subgroup analysis showed that average performance alone was insufficient for safe deployment. The framework maps medication and clinical inputs to FHIR resources and produces an explanation packet that identifies risk level, contributing medicines, interaction mechanisms, renal-dose concerns, data quality and recommended human review. The study offers a transparent foundation for prospective validation in nursing homes, ambulatory geriatric practice and post-acute care.},
      keywords = {Polypharmacy, Medication Safety, Older Adults, Potentially Inappropriate Medications, Adverse Drug Events, Falls, Renal Dosing, Explainable Artificial Intelligence, FHIR, Clinical Decision Support.},
      month = {July},
      doi = {https://doi.org/10.64388/IREV10I1-1720286}
  }